Critical Limb Ischemia (CLI/CLTI) - 7MM Market Insights, Epidemiology, and Forecast to 2036 | Rising Disease Burden and Regenerative Therapies Open New Growth Opportunities
Dublin, Oct. 09, 2026 (GLOBE NEWSWIRE) -- "Critical Limb Ischemia - Market Insight, Epidemiology, and Market Forecast - 2036" has been added to ResearchAndMarkets.com's offering.
Thereport provides a comprehensive assessment of the critical limb ischemia (CLI) market across the 7MM, comprising the United States, Germany, Spain, Italy, France, the United Kingdom, and Japan. The analysis covers historical and forecasted epidemiology, treatment practices, emerging therapies, market access, competitive dynamics, and commercial opportunities from 2022-2036.
Critical limb ischemia, increasingly referred to as chronic limb-threatening ischemia (CLTI), is the most advanced stage of peripheral arterial disease (PAD). It is associated with ischemic rest pain, non-healing wounds, tissue loss, gangrene, major amputation risk, and substantial mortality. Disease progression is influenced by aging, diabetes mellitus, smoking, obesity, dyslipidemia, hypertension, and sedentary lifestyles. CLI also frequently occurs alongside coronary artery disease, cerebrovascular disease, and chronic kidney disease, reflecting its association with systemic atherosclerosis.
CLI Epidemiology and Patient Burden
The annual incidence of CLI in the general population is estimated at approximately 22 per 100,000 people, increasing to around 100-200 per 100,000 annually among adults aged 65 years and older. US Medicare data indicate an overall prevalence of approximately 0.23%, rising from 0.13% among individuals aged 65-69 years to 0.31% among those aged 85 years and older. Diabetes contributes disproportionately to CLI-related limb events and amputations because of accelerated peripheral arterial disease and microvascular dysfunction.
Evidence from the United Kingdom also demonstrates a strong age-related increase in disease burden, particularly among people aged 75 years and older. In Japan, approximately 28% of PAD patients undergoing endovascular therapy have presented with CLI, while about 5% have progressed from intermittent claudication to CLI. Across the 7MM, aging populations and the growing prevalence of diabetes and cardiovascular risk factors are expected to sustain demand for effective limb-salvage treatments.
Diagnosis and Current CLI Treatment Landscape
Diagnosis combines clinical evaluation with hemodynamic testing and vascular imaging. Common assessments include ankle-brachial index (ABI), toe-brachial index (TBI), toe pressure measurements, duplex ultrasound (DUS), CT angiography (CTA), and MR angiography (MRA). These methods support disease staging, anatomical assessment, risk stratification, and revascularization planning.
CLI treatment focuses on restoring limb perfusion, relieving pain, supporting wound healing, preventing infection, and reducing amputation risk. Endovascular revascularization remains a principal intervention and includes plain or drug-coated balloon angioplasty, bare-metal or drug-eluting stents, and atherectomy. Surgical bypass is used for appropriate patients with complex or advanced arterial lesions.
Adjunctive care includes antiplatelet therapy, statins, selected anticoagulation, wound management, infection control, analgesics, and optimization of diabetes, hypertension, lipid levels, and smoking-related risks. Prostanoids may be considered in selected refractory cases. Primary amputation remains necessary when tissue damage is irreversible or limb salvage is not feasible.
CLI Market Drivers and Unmet Needs
The CLI market remains procedure-driven, with revascularization accounting for a significant share of clinical management. However, mechanical restoration of blood flow does not fully address progressive vascular degeneration. The lack of broadly approved pharmacological options creates a substantial opportunity for therapies capable of improving microvascular repair, perfusion, wound healing, and long-term limb salvage.
CLI Pipeline and Competitive Landscape
The critical limb ischemia pipeline includes angiogenic proteins, gene therapies, stem or progenitor cell therapies, and chemokine-based approaches. Development activity remains focused on patients who have limited or no revascularization options.
Collategene, an HGF plasmid gene therapy approved in Japan, represents an important development in the regenerative treatment landscape. Broader market growth will depend on clinical efficacy, safety, durability, regulatory outcomes, manufacturing feasibility, pricing, reimbursement, and physician adoption.
CLI Market Forecast and Commercial Analysis
The report evaluates the 2025 critical limb ischemia market baseline and forecasts market development through 2036. It includes country-level market sizing, therapy-specific revenue projections, market share analysis, peak patient share, expected drug uptake, addressable patient populations, and compound annual growth assessments. Forecasting is supported by epidemiology-based, bottom-up methodology and analysis of clinical, regulatory, and commercial assumptions.
Drug uptake analysis examines the anticipated performance of emerging CLI therapies during 2026-2036, including launch timing, adoption barriers, peak penetration, eligible patient populations, and potential sales. Particular attention is given to no-option patients, who represent a clinically urgent and commercially significant segment.
Market Access, Reimbursement, and Pricing
The report assesses country-specific accessibility, reimbursement pathways, cost-effectiveness, out-of-pocket expenses, and public insurance coverage. It also reviews potential payment models for high-cost regenerative and advanced therapies. Pricing and analogue analysis considers comparable treatments, expected clinical value, geographic pricing variation, affordability, adherence, and long-term uptake.
Expert Validation and Strategic Assessment
Primary research incorporates insights from more than 10 Key Opinion Leaders and Subject Matter Experts across major markets. Expert perspectives address treatment practices, patient selection, emerging therapy adoption, clinical development, accessibility, adherence, epidemiology, and real-world prescribing patterns.
SWOT and conjoint analyses evaluate the CLI competitive landscape and rank emerging therapies according to efficacy, safety, administration frequency, route of administration, order of entry, probability of success, and addressable patient population. These findings support pipeline prioritization, market entry planning, product positioning, and investment decisions.
Key Report Deliverables
The report supports pharmaceutical companies, biotechnology developers, investors, healthcare providers, and market access teams seeking to understand the evolving CLI market. Its integrated assessment of patient burden, clinical development, treatment adoption, reimbursement, and competitive positioning identifies opportunities for therapies designed to improve perfusion, reduce amputations, and deliver more durable outcomes through 2036.
Key Topics Covered
1. Key Insights
2. Report Introduction
3. Executive Summary
4. Key Events
4.1. Upcoming Key Catalyst
4.2. Key Conferences And Meetings
4.3. Key Transactions And Collaborations
4.4. News Flow
5. Epidemiology and Market Methodology of CLI
6. CLI Market Overview at a Glance
6.1. Clinical Landscape Analysis (By Molecule Type, Phase, and Route of Administration [ROA])
6.2. Market Share of CLI By Therapies (%) in the 7MM in 2025
6.3. Market Share of CLI By Therapies (%) in the 7MM in 2036
7. Disease Background And Overview of CLI
7.1. Introduction
7.2. Classification
7.3. Causes
7.4. Signs and Symptoms
7.5. Pathophysiology
7.6. Clinical features
7.7. Diagnosis
7.7.1. Diagnostic Guidelines
7.7.2. Diagnostic Algorithm
7.8. Treatment and Management
7.8.1. Treatment Guidelines and Recommendations
8. Epidemiology and Patient Population of CLI
8.1. Key Findings
8.2. Assumptions and Rationale: The 7MM
8.2.1. CLI Diagnosed Prevalent Cases in the 7MM
8.3. The US
8.3.1. CLI Prevalent Cases in the United States
8.3.2. CLI Diagnosed Prevalent Cases in the United states
8.3.3. CLI Age-specific Cases in the United States
8.3.4. CLI Severity-specific Cases in the United States
8.3.5. CLI Total Treated Cases in the United States
8.4. EU4 and the UK
8.4.1. CLI Prevalent Cases in EU4 and the UK
8.4.2. CLI Diagnosed Prevalent Cases in EU4 and the UK
8.4.3. CLI Age-specific Cases in EU4 and the UK
8.4.4. CLI Severity-specific Cases in EU4 and the UK
8.4.5. CLI Total Treated Cases in EU4 and the UK
8.5. Japan
8.5.1. CLI Prevalent Cases in the Japan
8.5.2. CLI Diagnosed Prevalent Cases in the Japan
8.5.3. CLI Age-specific Cases in the Japan
8.5.4. CLI Severity-specific Cases in the Japan
8.5.5. CLI Total Treated Cases in the Japan
9. Patient Journey of CLI
10. Emerging Therapies
10.1. Competitive Landscape: Emerging Therapies
10.2. ACP-01: Hemostemix
10.2.1. Product Description
10.2.2. Other Developmental Activities
10.2.3. Clinical Development
10.2.4. Safety and Efficacy
10.2.5. Analyst's View
11. CLI: Seven Major Market Analysis
11.1. Key Findings
11.2. Market Outlook
11.3. Conjoint Analysis
11.4. Key Market Forecast Assumptions
11.4.1. Cost Assumptions and Rebate
11.4.2. Pricing Trends
11.4.3. Analogue Assessment
11.4.4. Launch Year and Therapy Uptake
11.5. Total Market Size of CLI in the 7MM
11.6. United States Market Size
11.6.1. Total Market Size of CLI in the United States
11.6.2. Market Size of CLI by Therapies in the United States
11.7. EU4 and the UK Market Size
11.7.1. Total Market Size of CLI in EU4 and the UK
11.7.2. Market Size of CLI by Therapies in EU4 and the UK
11.8. Japan Market Size
11.8.1. Total Market Size of CLI in Japan
11.8.2. Market Size of CLI by Therapies in Japan
12. Unmet Needs of CLI
13. SWOT Analysis of CLI
14. KOL Views of CLI
14.1. Expert/KOL Interview Highlights
15. Market Access and Reimbursement of CLI
15.1. United States
15.1.1. Centre for Medicare and Medicaid Services (CMS)
15.2. EU4 and the UK
15.2.1. Germany
15.2.2. France
15.2.3. Italy
15.2.4. Spain
15.2.5. United Kingdom
15.3. Japan
15.4. Summary and comparison of Market Access and Pricing Policy Developments in 2025
15.5. Market Access and Reimbursement of CLI Therapies
16. Appendix
16.1. Bibliography
16.2. Report Methodology
17. Analyst's Capabilities
18. Disclaimer
19. About the Publisher
List of Tables [66]
List of Figures [70]
A selection of companies mentioned in this report includes, but is not limited to:
For more information about this report visit https://www.researchandmarkets.com/r/1kv8ns
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.